Growth in personalised medicine to drive alliances between diagnostic and pharmaceutical industries

25 August 2009 — The growth of personalised medicine, which aims to better target treatments to patients, is expected to increase the number of alliances between diagnostic and pharmaceutical businesses, according to a new PricewaterhouseCoopers (PwC) report entitled Diagnostics 2009:  Moving towards personalised medicine. This trend is evidenced by GlaxoSmithKline’s recently announced deal with Enigma, a British diagnostics group, to develop a new test which can diagnose specific strains of influenza, including swine flu, in just an hour.

Although the effort to better personalise treatments is not new, significant further progress is needed as current patient response rates to medicines can be very low – varying from 20% to 75% depending on the drug.

Alina Lavrentieva, partner, leader of pharmaceutical industry practice, PricewaterhouseCoopers, commented:

 “We expect alliances with the pharmaceutical industry to increase in the next two to five years but this will be driven by factors including the pricing of diagnostics, the extent of reimbursement coverage, and the burden of any clinical validation work required for market access.

“Although the clinical motivation for developing more tests designed to guide the prescribing of a specific drug is clear, the economics are challenging. The pricing of these tests does not always reflect the level of development costs associated with the test or its contribution to overall health benefits and this can adversely affect the business case for developing a new diagnostic.

‘’Addressing the pricing conundrum is a  crucial factor to  ensure that diagnostics play a full part in improving patient health and will be a critical part of a pharmaceutical company’s tool kit in enhancing its product portfolio and pipeline.”

The report highlights the prominence of personalised medicine in current mergers and acquisitions (M&A) and licensing deal activity in the in vitro diagnostics (IVD) sector. In 2008, personalised medicine motivated three of the ten largest M&A deals and four of the licensing deals by the ten largest IVD companies.

PwC expects a number of factors to drive the continued development of personalised medicine and the value of innovative diagnostics, including:

• Regulatory agencies, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA), which are supporting the field of personalised medicine by introducing formal requirements to test for certain biomarkers prior to prescribing certain drugs.
• Legislation introduced in May 2008 in the US and Europe to protect individuals against discrimination resulting from the use of genetic information may now encourage more people to undergo genetic testing or participate in innovative research.
• Genentech’s Citizen Petition of December 2008, which created new momentum around the discussion of the diversity of regulatory paths to market for in vitro diagnostics.
• The formal adoption of new diagnostic technologies in the guidelines of important clinical communities, which should accelerate their market adoption. Agendia’s MammaPrint (a DNA-based test for evaluating an individual’s risk of breast cancer spreading to other sites) is an example of a new diagnostic tool to help personalise treatment, which was recently validated by an influential national clinical group—the Dutch Institute for Healthcare Improvement (CBO).

Alina Lavrentieva, partner, pharmaceutical industry, PricewaterhouseCoopers, concluded:

“Increasingly, pharmaceutical companies will not move a drug candidate to the clinical development stage without a clear biomarker development program. These companies understand the contribution of biomarkers and diagnostics in improving the design and probability of success of clinical trials. In addition, pressure from healthcare payers is putting more emphasis on the availability of a companion biomarker test when deciding on a drug’s reimbursement. These factors will combine to accelerate the development of new diagnostics for personalised medicine. Together we anticipate that alliances and collaboration will be inevitable as the market need expands.”

Notes to editor:

1. For additional information, please contact Anna Kogosova, PR Assistant Manager.
2. Download a full copy of the report Diagnostics 2009: Moving towards personalised medicine.
3. PricewaterhouseCoopers provides industry-focused assurance, tax and advisory services to build public trust and enhance value for its clients and their stakeholders. More than 163,000 people in 151 countries across our network share their thinking, experience and solutions to develop fresh perspectives and practical advice.

'PricewaterhouseCoopers' refers to the network of member firms of PricewaterhouseCoopers International Limited, each of which is a separate and independent legal entity.